Antigenics Oncophage Renal Cancer Pivotal Trial Planned For Mid-2000
Executive Summary
Antigenics plans to initiate the first pivotal trial for its patient-specific immunotherapeutic agent Oncophage in mid-2000 for renal cancer therapy, the company stated in the prospectus for its planned $46 mil. initial public offering.